Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...

ApoCell established its ApoCell Europe GmbH European division, which partnered with not-for-profit Fraunhofer IZI to develop ApoCell's ApoStream . The detection device using dielectrophoresis field flow fractionation to isolate and recover circulating tumor cells (CTCs). The...

Nuvo said it received €4.4 million ($5.3 million) in funding from the Development Bank of Saxony (SAB) in Germany. The funding will cover development expenses for a reformulated version of WF10 , including CMC activities and...

Dendreon Corp. (NASDAQ:DNDN) gained $0.06 to $35.13 last week after a technology assessment released for this Wednesday's meeting of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) said there is moderately strong evidence that...

Top-line data from a double-blind, German Phase II trial in 60 patients with a >=2 year history of persistent allergic rhinitis and a positive allergen skin test showed that once-daily WF10 for 5 consecutive days...

Nuvo Research Inc. (TSX:NRI) said once-daily WF10 for five consecutive days met the primary endpoint of significantly improving Total Nasal Symptom Score from baseline to three weeks vs. placebo in a Phase II trial to...

Nuvo began a double-blind, placebo-controlled, European Phase II trial in 50 patients to evaluate once-daily WF10 for 5 consecutive days. Nuvo is co-developing WF10 for allergic rhinitis with the Fraunhofer Institute for Cell Therapy and...

Cytori and the institute will use Cytori’s Celution System technology to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The institute will provide $425,000 over two years, and Cytori will contribute an undisclosed...